Pfizer Inc. (NYSE:PFE) Shares Sold by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 17.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,820 shares of the biopharmaceutical company’s stock after selling 14,630 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Pfizer were worth $1,914,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Swedbank AB grew its position in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares during the period. Elevated Capital Advisors LLC boosted its position in Pfizer by 6.7% during the third quarter. Elevated Capital Advisors LLC now owns 23,198 shares of the biopharmaceutical company’s stock worth $671,000 after purchasing an additional 1,460 shares in the last quarter. McAdam LLC grew its holdings in Pfizer by 13.9% in the third quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 2,628 shares during the period. Heartland Bank & Trust Co increased its position in shares of Pfizer by 8.3% in the third quarter. Heartland Bank & Trust Co now owns 23,068 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,777 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $146,481,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $25.86 on Friday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market cap of $146.52 billion, a PE ratio of 18.34, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day moving average price of $26.28 and a 200 day moving average price of $27.44.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the company earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.65%. Pfizer’s payout ratio is 121.99%.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Guggenheim reissued a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Finally, Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.